Mark Leonard Singleton - Mar 15, 2024 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
SVP & CFO
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Stock symbol
BVS
Transactions as of
Mar 15, 2024
Transactions value $
$0
Form type
4
Date filed
3/22/2024, 05:22 PM
Previous filing
Jun 22, 2023
Next filing
Mar 25, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Award $0 +80.6K $0.00 80.6K Mar 15, 2024 Class A Common Stock 80.6K Direct F1, F2
transaction BVS Restricted Stock Units Award $0 +42.2K $0.00 42.2K Mar 15, 2024 Class A Common Stock 42.2K Direct F1, F3
transaction BVS Stock Option (Right to Buy) Award $0 +182K $0.00 182K Mar 15, 2024 Class A Common Stock 182K $5.45 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 The RSUs and options, as applicable, shall vest in four approximately equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
F3 The RSUs shall vest on June 15, 2024, subject to the Reporting Person continuing in service through the applicable vesting date.